8-K: TNF Pharma Pivots to Crypto with LightSolver Tech, Secures $7M

TNF Pharmaceuticals announced a strategic pivot into cryptocurrency mining with exclusive rights to LightSolver's laser-based computing technology, supported by a $7 million private placement and a 1-for-100 reverse stock split.

Summary

• Completed a 1-for-100 reverse stock split on August 29, 2025, to comply with Nasdaq listing standards, reducing outstanding common shares from 178,615,658 to 1,786,157.
• Secured $7,000,000 in gross proceeds through a private placement of 7,000 shares of Series H convertible preferred stock (stated value $1,000 per share) and accompanying warrants to purchase up to 1,400,000 common shares.
• Acquired 100% of LPU Holdings LLC, which holds an exclusive global license from LightSolver Ltd. for its proprietary laser-based computing technology in cryptocurrency and blockchain applications.
• LPU will pay LightSolver up to $8,500,000 in non-recurring engineering fees upon milestone achievement, plus a one-time cash payment of the greater of 25% of private placement proceeds or $1,500,000.
• Amended Series F and F-1 convertible preferred stock terms, extending their maturity date to March 2, 2027, and removing amortization payments and related terms/covenants.
• Terminated the Master Service and Technology Agreement with Prevail InfoWorks, Inc. for its Phase 2 clinical study of isomyosamine in sarcopenia/frailty.

Sentiment

Score: 7

Explanation: The strategic pivot into a high-growth, innovative technology sector (photonic computing for crypto) is a significant positive, backed by a substantial capital raise. However, the necessity of a reverse stock split for Nasdaq compliance and the termination of a clinical trial for a legacy drug indicate past challenges and a complete change in business model, which carries inherent risks and uncertainty. The potential for high dilution from the new securities is also a concern.

Positives

• Strategic pivot into the high-growth cryptocurrency and blockchain sector with exclusive global rights to innovative laser-based computing technology from LightSolver.
• LightSolver's technology is recognized by the World Economic Forum and Gartner, suggesting strong potential and validation.
• The laser-based computing system is designed to offer significant speed and efficiency advantages over traditional GPUs, quantum computing, and HPC, with up to 90% energy cost reduction for crypto applications.
• Successful private placement raising $7,000,000, indicating investor confidence in the new strategic direction and providing working capital.
• Strengthened financial position enables opportunistic business developments and pursuit of new ventures.
• The company is in late-stage discussions with a tech infrastructure and crypto mining expert to lead development and commercialization strategy for the licensed technology.

Negatives

• A 1-for-100 reverse stock split was necessary for Nasdaq listing compliance, which often indicates a low share price and potential underlying financial or operational challenges.
• Significant potential dilution from the conversion of Series H preferred stock (initially convertible into 1,400,000 common shares at $5.00) and warrants (exercisable for 1,400,000 common shares at $5.00).
• Further dilution from Series I preferred stock (convertible into 747,362 common shares) issued for the LPU acquisition and potential contingent Milestone Securities.
• Termination of the clinical services agreement for the isomyosamine Phase 2 study suggests a de-prioritization or cessation of this legacy therapeutic platform, potentially abandoning prior R&D investments.
• High fees for placement agents (4% or 5%/2.5% cash plus warrants) for the private placement, impacting net proceeds.
• Substantial non-recurring engineering fees (up to $8,500,000) and an upfront cash payment (greater of 25% of private placement proceeds or $1,500,000) to LightSolver, representing significant upfront costs for the new venture.

Risks

• Failure to obtain stockholder approval for the issuance of common stock exceeding 19.99% of outstanding shares, as required by Nasdaq listing standards, could limit conversions and exercises of new securities.
• The success of the new cryptocurrency and blockchain venture is highly dependent on the unproven commercialization of LightSolver's technology in this specific application.
• The company's ability to maintain compliance with Nasdaq listing standards remains a risk, despite the reverse stock split.
• The company faces risks associated with its legacy therapeutic platforms, including the timing and ability to obtain regulatory approvals for clinical trials and the amount of funds required.
• Increased levels of competition in both the pharmaceutical and the new technology/cryptocurrency sectors.
• Changes in political, economic, or regulatory conditions, particularly in the rapidly evolving cryptocurrency market, could adversely impact the new business.
• Ability to retain and attract senior management and key employees, especially with the strategic shift, is crucial for successful execution.
• Risks related to protecting intellectual property and operating without infringing on others' rights in the new technology domain.
• Potential for 'Triggering Events' (e.g., trading suspension, failure to pay dividends, breach of covenants, bankruptcy) which could lead to mandatory redemption of preferred shares at a premium, creating significant financial obligations.
• The company is subject to a covenant requiring it to maintain a minimum unencumbered, unrestricted cash and cash equivalents balance of at least $500,000.
• Default under indebtedness or judgments against the company exceeding $250,000 could trigger adverse events.

Future Outlook

The company expects to use the net proceeds from the private placement for general corporate purposes and working capital. It intends to change its name to reflect its new venture into cryptocurrency and blockchain applications. The company is in late-stage discussions with a tech infrastructure and crypto mining expert to lead the development and commercialization strategy for its licensed technology. It believes it is positioned to capitalize on the strong momentum behind photonic computing and the future of cryptocurrency infrastructure, aiming for first-mover advantages and growth. The company will continue to evaluate strategic options for its legacy therapeutic platforms (isomyosamine and Supera-CBD) to maximize shareholder value.

Management Comments

• "With LightSolvers LPUs, we believe compute-intensive combinatorial and physical problems can be solved at the speed of light—orders of magnitude faster than other methods. At the same time, crypto infrastructure is still using outdated tools that arent tailored for crypto applications. We are excited to partner with TNF to develop what we believe to be the first light-based computing system to blockchain." Dr. Ruti Ben-Shlomi, CEO of LightSolver.
• "We believe LightSolver has created a disruptive computing paradigm that opens a new world of light speed computation. Our new partnership with LightSolver gives us exclusive access to quantum-inspired LPU-based systems capable of unlocking unprecedented performance and sustainability for the cryptocurrency industry." Joshua Silverman, TNF's Executive Chairman.
• "Our recent significant improvements in TNFs financial position enable us to be opportunistic in our business developments." Joshua Silverman, TNF's Executive Chairman.
• "With LightSolver, we believe we are positioned to capitalize on the strong momentum behind both photonic computing and the future of cryptocurrency infrastructure. We believe we now have first mover advantages in a burgeoning industry—a strategy that we believe best positions TNF for growth and value creation." Joshua Silverman, TNF's Executive Chairman.
• "We believe LightSolvers computing leap is similar in significance to technologys upgrade from slow form dial-up internet to high-speed fiber internet. Our LPUs tackle problems that are unfeasible for classical supercomputers due to their memory bottlenecks and energy inefficiency. For cryptocurrency applications, laser-based computing is intended to reduce heat and power waste with the speed and efficiency of light—transforming how mining, proof-of-work, and decentralized computing scale." Dr. Ruti Ben-Shlomi, CEO of LightSolver.

Industry Context

This announcement signifies a major strategic shift for TNF Pharmaceuticals, moving from a clinical-stage biopharmaceutical company to a technology company focused on cryptocurrency and blockchain applications. The licensing of LightSolver's laser-based computing technology positions TNF to enter the rapidly evolving photonic computing and crypto mining sectors. LightSolver's recognition by the World Economic Forum and Gartner highlights the innovative nature of this technology, which aims to address the energy inefficiency and computational limitations of current cryptocurrency infrastructure. This move aligns with broader industry trends exploring advanced computing solutions for complex problems and sustainable practices in energy-intensive fields like crypto mining.

Comparison to Industry Standards

• LightSolver's LPU technology is designed to outperform conventional GPUs, quantum computing, and high-performance computing (HPC) in speed and efficiency for compute-intensive combinatorial and physical problems.
• The laser-based computing system is intended to reduce energy costs by up to 90% in cryptocurrency applications, offering a potential pathway to fully sustainable infrastructure, which is a significant improvement over current energy-intensive crypto mining methods.
• LightSolver's LPU operates in a highly parallel mode with a clock-time of a few nanoseconds, contrasting with the memory bottlenecks and energy inefficiency of classical supercomputers.
• The LPU is less demanding in terms of environmental conditions, requiring no vacuum or ultracold temperatures, unlike some quantum computing systems.
• The LPU is compact, described as the size of a rack unit, which could offer space efficiency advantages.

Management Changes

Corporate Governance

Related Party Transactions

• PharmaCyte Biotech, Inc., an entity affiliated with Joshua Silverman (Executive Chairman), purchased 3,000 shares of Series H Preferred Stock and accompanying warrants to purchase 600,000 shares of Common Stock for an aggregate purchase price of $3,000,000 in the private placement.

Stakeholder Impact

• Shareholders: Will experience significant dilution from the private placement and acquisition, especially if preferred shares convert. The reverse stock split aims to maintain Nasdaq listing, which is positive for liquidity, but reduces the number of shares held. The strategic pivot introduces a new risk/reward profile for their investment.
• Employees: Management changes (President, new Board member, Executive Chairman appointment) could signal shifts in company culture or operational focus. The pivot to a new industry may require new skill sets or lead to changes in existing roles.
• Customers (legacy pharma): The termination of the clinical services agreement for isomyosamine suggests a potential slowdown or cessation of development for this therapeutic candidate, impacting potential future patients.
• Investors (new): New investors in the private placement gain exposure to the new crypto/photonic computing venture, with specific preferred stock and warrant terms that define their rights and potential returns.
• Creditors: Amendments to Series F and F-1 preferred stock extend maturity dates and remove amortization payments, potentially easing short-term financial pressure on the company but extending the repayment period for these creditors.

Next Steps

• Closing of the private placement and the acquisition of LPU Holdings LLC, expected on September 4, 2025.
• Seeking stockholder approval for the issuance of more than 19.99% of outstanding common stock related to the private placement by November 16, 2025.
• Seeking stockholder approval for the issuance of shares related to the LPU acquisition no later than 60 days following the closing of the acquisition.
• Filing a resale registration statement for the Series H preferred stock conversion shares and warrants within 15 calendar days after the closing date of the private placement.
• Filing a resale registration statement for the Series I preferred stock conversion shares within 30 calendar days after the closing date of the LPU acquisition.
• Developing and commercializing the licensed laser-based computing technology for cryptocurrency applications.
• Pursuing a company name change to reflect the new strategic direction.
• Continuing to evaluate strategic, value-enhancing options for legacy therapeutic platforms (isomyosamine and Supera-CBD).

Key Dates

Recommendation

The company is undergoing a radical strategic transformation, pivoting from a clinical-stage biopharmaceutical company to a technology firm focused on cryptocurrency mining with laser-based computing. While the new venture with LightSolver presents an intriguing opportunity in a high-growth sector with potentially disruptive technology, the execution risk is substantial. The reverse stock split, while necessary for Nasdaq compliance, often signals underlying financial distress or a lack of investor confidence in the previous business model. The significant dilution from the private placement and acquisition, coupled with the unproven commercialization path of the new technology, creates considerable uncertainty. Investors should 'hold' to observe the initial progress of this strategic pivot, the successful integration of LightSolver's technology, and the company's ability to execute on its new business model before making further investment decisions. The long-term viability of the new direction needs to be demonstrated.

Keywords

TNF Pharmaceuticals, TNFA, SEC Filing, 8-K, Reverse Stock Split, Private Placement, Convertible Preferred Stock, Warrants, LightSolver, Laser Processing Unit, LPU, Cryptocurrency Mining, Blockchain, Photonic Computing, Corporate Strategy, Capital Raise, Nasdaq Compliance, Dilution, Corporate Governance, Management Change, Pharmaceuticals, Isomyosamine, Supera-CBD, Acquisition, LPU Holdings